Uğur Şahin, BioNTech CEO (Frank Rumpenhorst/dpa via AP Images)
December 9, 2021 09:18 AM ESTUpdated 03:53 PM
Discovery
Coronavirus

Will ‘orig­i­nal anti­genic sin’ un­der­mine Omi­cron boost­ers? New re­search sug­gests ‘no’

Jason Mast

Editor

Mod­er­na and Pfiz­er-BioN­Tech are now rac­ing to de­vel­op Omi­cron-spe­cif­ic boost­ers, hop­ing to be ready if the new im­mune-eva­sive vari­ant be­comes dom­i­nant glob­al­ly. But it wasn’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

Ex­clu­sive: For­mer Mer­ck sci­en­tists raise $85M to map and drug pro­tein in­ter­ac­tions in can­cer and au­toim­mune dis­ease

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times